US 11,938,117 B2
Magnesium biotinate compositions and methods of use
Deanna J. Nelson, Raleigh, NC (US); and James R. Komorowski, Trumbull, CT (US)
Assigned to Nutrition21, LLC, Saddle Brook, NJ (US)
Filed by NUTRITION 21, LLC, Harrison, NY (US)
Filed on Aug. 31, 2017, as Appl. No. 15/693,223.
Claims priority of provisional application 62/382,438, filed on Sep. 1, 2016.
Prior Publication US 2018/0071264 A1, Mar. 15, 2018
Int. Cl. A61K 31/4188 (2006.01); A61G 3/00 (2006.01); A61K 8/19 (2006.01); A61K 8/67 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61Q 3/00 (2006.01); A61Q 5/00 (2006.01); A61Q 7/00 (2006.01)
CPC A61K 31/4188 (2013.01) [A61K 8/19 (2013.01); A61K 8/673 (2013.01); A61K 9/0053 (2013.01); A61K 9/2086 (2013.01); A61K 9/28 (2013.01); A61K 9/2806 (2013.01); A61Q 3/00 (2013.01); A61Q 5/002 (2013.01); A61Q 7/00 (2013.01); A61K 2800/58 (2013.01)] 27 Claims
OG exemplary drawing
 
1. A powder composition comprising:
isolated crystalline or isolated amorphous magnesium biotinate; and
optionally a pharmaceutically acceptable vehicle, carrier, or diluent.